Correlation between levels of C-reactive protein and clinical activity in Crohn's disease

Digestive and Liver Disease

Volumn 39, Issue 11, 2007, Pages 1006-1010

  Karoui, S ^a   Ouerdiane, S ^a   Serghini, M ^a   Jomni, T ^a   Kallel, L ^a   Fekih, M ^a   Boubaker, J ^a   Filali, A ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

C reactive protein; Crohn's disease; Disease activity

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; FIBRINOGEN; MESALAZINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 35548955053     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.06.015     Document Type: Article

References (23)

1. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., and Pera A. Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 17 Suppl. 2 (2003) 11-17
2. Best W.R., Becktel J.M., Singleton J.W., Kern Jr. F., and National Cooperative Crohn's Disease Study. Development of a Crohn's disease activity index. Gastroenterology 70 (1976) 439-444
3. Vermeire S., Van Assche G., and Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 55 (2006) 426-431
4. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
5. Chamouard P., Richert Z., Meyer N., Rahmi G., and Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 882-887
6. Tromm A., Tromm C.D., Huppe D., Schwegler U., Krieg M., and May B. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 27 (1992) 774-778
7. Mehdi A., Baccouche A., Skandrani K., Bdioui F., Ghilene A., Ben Chaikha S., et al. Epidémiologie des maladies inflammatoires cryptogénétiques de l'intestin dans le Centre-Est Tunisien. Maghreb Médical 314 (1997) 47-52
8. Zouiten-Mekki L., Zouali H., Boubaker J., Karoui S., Fekih M., Matri S., et al. CARD15/NOD2 in a Tunisian population with Crohn's disease. Dig Dis Sci 1 (2005) 130-135
9. De Dombal F.T., and Softley A. Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 28 (1987) 474-481
10. Vermeire S., Van Assche G., and Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 661-665
11. Tall A.R. C-reactive protein reassessed. N Engl J Med 350 (2004) 1450-1452
12. Thalmaier D., Dambacher J., Seiderer J., Konrad A., Schachinger V., Pfennig S., et al. The +1059G/C polymorphism in the C-reactive protein gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmcol Ther 24 (2006) 1105-1115
13. Fagan E.A., Dyck R.F., Maton P.N., Hodgson H.J., Chadwick V.S., Petrie A., et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 12 (1982) 351-359
14. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al., the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicenter study of 121 cases. Gut 35 (1994) 231-235
15. Colombel J.F., Solem C.A., Sandborn W.J., Booya F., Loftus E.V., Harmsen W.S., et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by CT enterography: correlation with endoscopic severity and C-reactive protein. Gut 55 (2006) 1561-1567
16. Pallotta N., Tomei E., Viscido A., Calabrese E., Marcheggiano A., Caprilli R., et al. Small intestine contrast ultrasonography. An alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 11 (2005) 146-153
17. Haber H.P., Busch A., Ziebach R., and Stern M. Bowel wall thickness measured by ultrasound as a marker of Crohn's disease activity in children. Lancet 355 (2000) 1239-1240
18. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Fiasse R., et al. A positive response to Infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 17 (2002) 818-824
19. Sandborn W.J., Feagan B.G., Radford-Smith G., Kovacs A., Enns R., Innes A., et al. CDP-571, a humanised monoclonal antibody to tumor necrosis factor α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53 (2004) 485-493
20. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al., the CDP870 Crohn's Disease Study Group. A randomised, placebo-controlled trial of Certolizumab Pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
21. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S., Lawrance I.C., et al., for the International Efficacy of Naralizumab as Active Crohn's Therapy (ENACT-1) and the Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Groups. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
22. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lemann M., Mary J.Y., and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 12 (2006) 551-557
23. Florin T.H.J., Paterson E.W.J., Fowler E.V., and Radford-Smith G.L. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 41 (2006) 306-311